Breakthrough in Alzheimer's Disease Treatment

The Federal Drug Administration recently approved Lecanemab for Alzheimer's Disease treatment. In this video, Dr. S. Thomas Carmichael, Chair of the UCLA Department of Neurology, discusses who can take this drug, the effects, and next steps for patients interested in receiving treatment. Lecanemab targets and removes beta-amyloid proteins from the brain. Removing these proteins modestly slows the rate of cognitive decline. Eligible patients have mild cognitive impairment due to Alzheimer’s Disease or mild Alzheimer’s Disease. Lecanemab is not a preventative treatment or cure for Alzheimer’s Disease. Donanemab, another Alzheimer's Disease drug, has been submitted for FDA approval. To learn more about Alzheimer’s Disease treatment and care at UCLA, please call the UCLA Neurology Outpatient Clinic: 310-794-1195. You can also visit our website: https://www.uclahealth.org/department...